Urodynamic effects of silodosin, a new α_1A‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia

Abstract

Silodosin appears to improve detrusor overactivity and obstruction grade in patients with BPH. With silodosin treatment, LUTS could be managed effectively for more than a year in at least 44% of the patients.